COLLEGIUM PHARMACEUTICAL, INC·4

Dec 27, 7:17 PM ET

Heffernan Michael Thomas 4

4 · COLLEGIUM PHARMACEUTICAL, INC · Filed Dec 27, 2022

Insider Transaction Report

Form 4
Period: 2022-12-22
Transactions
  • Exercise/Conversion

    Common Stock

    2022-12-22$16.15/sh+237$3,82828,260 total
  • Exercise/Conversion

    Common Stock

    2022-12-23$16.15/sh+4,989$80,57233,012 total
  • Sale

    Common Stock

    2022-12-27$24.16/sh3,820$92,29128,023 total
  • Sale

    Common Stock

    2022-12-23$23.00/sh4,989$114,74728,023 total
  • Exercise/Conversion

    Common Stock

    2022-12-27$16.15/sh+15,995$258,31944,018 total
  • Exercise/Conversion

    Stock Option (Right to Purchase)

    2022-12-2223724,804 total
    Exercise: $16.15Exp: 2026-01-20Common Stock (237 underlying)
  • Exercise/Conversion

    Stock Option (Right to Purchase)

    2022-12-234,98919,815 total
    Exercise: $16.15Exp: 2026-01-20Common Stock (4,989 underlying)
  • Exercise/Conversion

    Stock Option (Right to Purchase)

    2022-12-2715,9953,820 total
    Exercise: $16.15Exp: 2026-01-20Common Stock (15,995 underlying)
  • Sale

    Common Stock

    2022-12-27$23.63/sh15,995$377,96228,023 total
  • Sale

    Common Stock

    2022-12-22$23.00/sh237$5,45128,023 total
  • Exercise/Conversion

    Common Stock

    2022-12-27$16.15/sh+3,820$61,69331,843 total
  • Exercise/Conversion

    Stock Option (Right to Purchase)

    2022-12-273,8200 total
    Exercise: $16.15Exp: 2026-01-20Common Stock (3,820 underlying)
Footnotes (5)
  • [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2022.
  • [F2]The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.00 to $23.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2).
  • [F3]The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.00 to $23.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3).
  • [F4]The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.00 to $24.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4).
  • [F5]The option, initially representing a right to purchase a total of 109,005 shares, is fully vested and exercisable.

Documents

1 file
  • 4
    form4.xmlPrimary

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES